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ABSTRACT
Background and objective: The aim of the Pulmonary
Rehabilitation Guidelines (Guidelines) is to provide
evidence-based recommendations for the practice of
pulmonary rehabilitation (PR) specific to Australian
and New Zealand healthcare contexts.
Methods: The Guideline methodology adhered to the
Appraisal of Guidelines for Research and Evaluation
(AGREE) II criteria. Nine key questions were con-
structed in accordance with the PICO (Population,
Intervention, Comparator, Outcome) format and
reviewed by a COPD consumer group for appropriate-
ness. Systematic reviews were undertaken for each
question and recommendations made with the strength
of each recommendation based on the GRADE
(Gradings of Recommendations, Assessment, Develop-
ment and Evaluation) criteria. The Guidelines were
externally reviewed by a panel of experts.
Results: The Guideline panel recommended that
patients with mild-to-severe COPD should undergo PR
to improve quality of life and exercise capacity and to
reduce hospital admissions; that PR could be offered in
hospital gyms, community centres or at home and could
be provided irrespective of the availability of a struc-
tured education programme; that PR should be offered
to patients with bronchiectasis, interstitial lung disease
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and pulmonary hypertension, with the latter in special-
ized centres. The Guideline panel was unable to make
recommendations relating to PR programme length
beyond 8 weeks, the optimal model for maintenance after
PR, or the use of supplemental oxygen during exercise
training. The strength of each recommendation and the
quality of the evidence are presented in the summary.
Conclusion: The Australian and New Zealand Pulmonary
Rehabilitation Guidelines present an evaluation of the
evidence for nine PICO questions, with recommendations
to provide guidance for clinicians and policymakers.
Key words: bronchiectasis, chronic obstructive pulmonary dis-
ease, exercise and pulmonary rehabilitation, guidelines, intersti-
tial lung disease.
Abbreviations: , 6MWT, 6-min walk test; AGREE, Appraisal of
Guidelines for Research and Evaluation; CINAHL, cumulative
index to nursing and allied health literature; COPD, chronic
obstructive pulmonary disease; CRQ, Chronic Respiratory
Disease Questionnaire; EID, exercise-induced oxygen
desaturation; EMBASE, Excerpta Medica dataBASE; FEV1, forced
expiratory volume in 1 s; GRADE, Gradings of
Recommendations, Assessment, Development and Evaluation;
HCU, healthcare utilization; HRQoL, health-related quality of life;
ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis;
ISWT, incremental shuttle walk test; LOS, length of stay; MD,
mean difference; MID, minimal important difference; mMRC,
modified MRC; MRC, Medical Research Council; PAH, pulmonary
arterial hypertension; PH, pulmonary hypertension; PICO,
Population, Intervention, Comparator, Outcome; PR, pulmonary
rehabilitation; QALY, quality-adjusted life year; RCT, randomized
controlled trial; SF-36v2, 36-Item Short Form Health Survey
version 2; SGRQ, St George’s Respiratory Questionnaire; SMD,
standardized MD; TSANZ, Thoracic Society of Australia and New
Zealand.
SUMMARY OF RECOMMENDATIONS
The Guideline panel recommends that:
1.
a. Patients with COPD should undergo pulmo-
nary rehabilitation (PR; strong recommenda-
tion, moderate quality evidence).
b. PR is provided after an exacerbation of COPD,
within 2 weeks of hospital discharge (weak rec-
ommendation, moderate quality evidence).
2. Patients with moderate-to-severe COPD (stable or
following discharge from hospital for an exacerbation
of COPD) should undergo PR to decrease hospitali-
zations for exacerbations (strong recommendation,
moderate-to-low quality evidence).
3.
a. Home-based PR be offered to patients with
COPD as an alternative to usual care (weak
recommendation, moderate-to-low quality
evidence).
b. Home-based PR, including regular contact to
facilitate exercise participation and progres-
sion, be offered to patients with COPD as an
alternative to hospital-based PR (weak recom-
mendation, moderate-to-low quality evidence).
c. Community-based PR, of equivalent frequency
and intensity as hospital-based programmes, be
offered to patients with COPD as an alternative
to usual care (weak recommendation, moderate
quality evidence).
4. Patients with mild COPD (based on symptoms)
undergo PR (weak recommendation, moderate-to-
low quality evidence).
5. The panel is unable to make a recommendation
due to lack of evidence evaluating whether pro-
grammes of longer duration are more effective
than the standard 8-week programmes.
6.
a. More research is needed to determine the opti-
mal model of maintenance exercise pro-
grammes (‘in-research’ recommendation).
b. Supervised maintenance programmes of monthly,
or less frequently, are insufficient to maintain the
gains of PR and should not be offered (weak rec-
ommendation, low quality evidence).
7. PR be offered to all patients with COPD, irrespective
of the availability of a structured multidisciplinary
group education programme (weak recommenda-
tion, moderate-to-low quality evidence).
8. Further research of oxygen supplementation during
training is required in patients with COPD who
have exercise-induced desaturation to reduce the
uncertainty around its lack of effect to date (‘in-
research’ recommendation).
9.
a. Patients with bronchiectasis undergo PR (weak
recommendation, moderate quality evidence).
b. Patients with interstitial lung disease undergo PR
(weak recommendation, low quality evidence).
c. Patients with pulmonary hypertension undergo
PR (weak recommendation, low quality evidence).
INTRODUCTION
COPD affects 1.5 million Australians, including 1 in
13 individuals over 40 years of age,1 with major conse-
quences for participation in work and societal con-
texts.2 The cost of COPD in Australia was estimated at
$8.8 billion in 2008/2009 (most recent figures), with
$929 million in direct health system expenditure,
largely due to hospital admissions.3 Indigenous
Australians (Aboriginal and Torres Strait Islander Peo-
ples) bear an unequal burden of disease in relation to
COPD. Compared with non-Indigenous Australians,
the prevalence of COPD is 2.5 times higher, with the
death rate being three times higher and the hospitaliza-
tion rate five times higher in Indigenous Australians.4
In New Zealand, COPD affects approximately 200 000
of the population with 14% of adults over 40 years of
age having COPD.5 The cost of COPD in New Zealand
is estimated as $NZ 5.6 billion with $NZ 484 million in
direct health system expenditure.5 Indigenous
New Zealanders (Maori) have a higher prevalence of
COPD, a 4.4 times higher rate of hospital admissions
and 2.2 times more deaths associated with the condi-
tion compared with non-Maori.5,6
Pulmonary rehabilitation (PR) is considered a key
component of the management of patients with
COPD7 and has been shown to reduce symptoms of
breathlessness and fatigue, improve health-related
quality of life (HRQoL)8 and reduce hospital
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readmissions after an exacerbation.9 However, uptake
of PR is estimated to be only 5–10% of those patients
with moderate-to-severe COPD who could benefit,10,11
related to lack of available programmes, poor referral
rates and poor patient uptake of existing programmes.
While international societies have published a number
of documents to guide practice in PR,12–15 none has
specifically addressed the provision of PR for patients
with COPD in the healthcare contexts of Australia or
New Zealand. In addition, a growing number of
patients with other chronic lung conditions such as
bronchiectasis, interstitial lung disease (ILD) and pul-
monary hypertension (PH) are referred to Australian
and New Zealand PR programmes. Evidence for the
benefits of PR in these conditions also needs to be
evaluated.
SCOPE AND PURPOSE
These Australian and New Zealand Pulmonary Rehabil-
itation Guidelines are primarily written for health prac-
titioners providing PR and for the much wider group of
health professionals who refer patients to PR in
Australia or New Zealand. The patient populations to
whom the Guidelines apply are those with chronic res-
piratory disease, primarily COPD, with some evidence
presented for patients with bronchiectasis, ILD and
PH. PR for patients with cystic fibrosis or lung cancer
was considered outside the scope of the Guidelines
due to the smaller body of evidence pertaining to struc-
tured PR for these groups.
METHODOLOGY
Members of the Australian Pulmonary Rehabilitation
Network of Lung Foundation Australia and members of
the Thoracic Society of Australia and New Zealand
(TSANZ) were invited to submit an expression of inter-
est to be considered for the Guideline panel. Partici-
pants were required to demonstrate expertise in PR
and ability to review literature. In total, 28 healthcare
professionals were appointed, with 11 of these forming
the lead panel members. The Guideline panel had the
following representation: 22 physiotherapists, 2 respira-
tory physicians, 1 health psychologist, 2 nurses and
1 exercise physiologist. Two members of the lead writ-
ing group (S.C.J. and A.E.H.) had specific expertise in
guideline methodology.
The proposal for writing the Australian and
New Zealand Pulmonary Rehabilitation Guidelines was
endorsed by the Clinical Care and Resources Subcom-
mittee of the TSANZ and the process was supported
and coordinated by Lung Foundation Australia. The
Guideline methodology adhered to the Appraisal of
Guidelines for Research and Evaluation (AGREE) II
criteria.16
The research questions addressed in the Guidelines
were based on the Guideline panel’s considered view
of the most important questions related to PR in
Australia and New Zealand, with the intention of limit-
ing the number of questions to <10. The questions
were constructed in accordance with the PICO
(Population, Intervention, Comparator, Outcome) for-
mat. There were nine main questions (Table 1), with
PICO questions 1–8 relating specifically to patients with
COPD and PICO question 9 addressing PR for patients
with bronchiectasis, ILD and PH. The questions were
reviewed by a COPD consumer group (Australian
COPD and Patient Advocate Group) which agreed that
the questions were appropriate.
Systematic literature searches
The definition of PR agreed by the Guideline panel, to
set the parameters for the minimum duration of PR for
the literature search, was that used in the most recent
Cochrane review: ‘Any in-patient, out-patient, commu-
nity-based or home-based rehabilitation programme of
at least four weeks’ duration that included exercise ther-
apy with or without any form of education and/or psy-
chological support delivered to patients with exercise
limitation attributable to COPD’.8
Systematic reviews were undertaken for each PICO
question using standard methodology,17 except for
questions 1 and 9. As the updated Cochrane review of
PR had recently been published,8 the data from that
review were used as the basis to answer question 1a
and the data from the updated Cochrane review on
hospital readmissions9 were used as a basis to answer
question 1b. Recently published systematic reviews of
PR for bronchiectasis,18 ILD19 and PH20 were used to
underpin question 9. Literature searches for all other
questions were undertaken with the assistance of uni-
versity librarians. The databases searched were Med-
line, PreMedline, EMBASE, OVID, CINAHL, Cochrane
and Scopus. The search terms for each question are
presented in Table S1 (Supplementary Information).
Tables of the studies reviewed for each question are
presented in Table S2 (Supplementary Information).
Studies were selected for inclusion in the review if they
were randomized controlled trials (RCTs) or systematic
reviews that directly addressed the questions. To be
included, studies had to report at least one of the pre-
specified outcomes of interest, such as exercise capac-
ity, HRQoL, healthcare utilization (HCU), anxiety and
depression or mortality.
Appraisal of literature
For each question, at least two members of the Guide-
line panel read the title and/or abstract of each article
from the literature search and decided whether to
include the article for full review. At least two reviewers
for each question independently extracted data from
the same studies. Additional information from authors
was requested if necessary. Risk of bias (high, low or
unclear risk) for each included study was evaluated
based on the following domains: random sequence
generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting or any
other bias. Where relevant, a meta-analysis was per-
formed to quantify effect size and certainty (Fig. S1,
Supplementary Information). Data and meta-analyses
from relevant, recent systematic reviews were used
when available. The quality of the body of evidence for
© 2017 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology
Respirology (2017) 22, 800–819








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Respirology (2017) 22, 800–819 © 2017 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































© 2017 The Authors
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology
Respirology (2017) 22, 800–819
804 JA Alison et al.
each recommendation was evaluated using the GRADE
(Gradings of Recommendations, Assessment, Develop-
ment and Evaluation) system21 which considered
within-study risk of bias, directness of evidence, heter-
ogeneity, precision of effect estimates and risk of publi-
cation bias (GRADE evidence tables are presented in
Table S3 (Supplementary Information)). The strength
of each recommendation was formulated based on the
GRADE criteria which considered the quality of the evi-
dence and trade-offs between desirable and undesira-
ble outcomes, confidence in effect estimates, patient
values and preferences and resource implications.22 In
GRADE methodology, ‘strong’ and ‘weak’ recommen-
dations are considered as categorical terminology on
an underlying continuum, with anchor categories of
‘strong against’, ‘weak against’, ‘weak for’ and ‘strong
for’.22 The evidence to recommendation tables that
detail the items considered when making the decision
regarding the strength of the recommendations are
presented in Table S4 (Supplementary Information)
and these tables should be read in conjunction with
each recommendation to provide the reader with the
reasoning behind the decision regarding the strength
of each recommendation. A ‘strong’ recommendation
means that all or almost all informed patients would
choose the recommended intervention as described;
adherence to this recommendation could be used in
clinical practice as a quality criterion or performance
indicator. A ‘weak’ recommendation means that most
informed patients would choose the recommendation
as described; clinicians must help each patient arrive at
a management decision consistent with his or her
values and preferences.23 An ‘in-research’ recommen-
dation means that there is insufficient evidence to rec-
ommend the intervention and more research could
clarify the effects of the intervention and would be
worthwhile.22
All members of the Guideline panel (n = 28) were
asked to vote on each recommendation as ‘agree’,
‘disagree’ or ‘abstain’. The voting results are shown
at the end of each of the evidence to recommenda-
tion tables in Table S4 (Supplementary Information).
After review of the Guidelines by an expert advisory
group, minor alterations were made to the text but
no major changes were made to the recommenda-
tions. The Guidelines were reviewed by the
New Zealand Cardiothoracic Physiotherapy Special
Interest Group, consumer representatives, the Clinical
Care and Resources Sub-Committee, Nursing, COPD,
Physiotherapy and OLIV Special Interest Groups of
TSANZ. The Australian and New Zealand Pulmonary
Rehabilitation Guidelines will be disseminated
through key stakeholder groups such as the Lung
Foundation Australia (including the Australian Pul-
monary Rehabilitation Network), Lung Foundation
New Zealand, Thoracic Society of Australia and
New Zealand, Australian Physiotherapy Association,
Physiotherapy New Zealand, Exercise and Sports Sci-
ence Association Australia, Sport and Exercise Sci-
ence New Zealand, Royal Australian College of
General Practitioners, Royal New Zealand College of
General Practitioners, Australian College of Nursing,
New Zealand Nurses Organisation, as well as through
clinicians registered to receive the COPD-X
Guidelines, university programmes that provide phys-
iotherapy and exercise physiology programmes. The
TSANZ will develop quality standards that will be
used to evaluate implementation and impact of the
Guidelines. The Australian and New Zealand Pulmo-
nary Rehabilitation Guidelines will be reviewed
within 5 years of publication to assess the need for
update.
PICO QUESTIONS
Background, Summary of evidence, Recommendation,
Justification and implementation
PICO 1: Is PR effective compared with usual
care in patients with COPD?
Background: Patients with COPD experience breath-
lessness, reduced functional capacity, reduced HRQoL
and poor psychological well-being. PR, incorporating
exercise training and education, is recommended for
patients with COPD with a view to improving breath-
lessness, exercise capacity, HRQoL and psychological
well-being.12,15 PR is typically commenced when a per-
son with COPD is in a stable phase; however, there is
increasing evidence that PR plays an important role fol-
lowing an exacerbation of COPD. In Australia and
New Zealand, PR following an exacerbation of COPD is
typically commenced in the outpatient setting, whereas
in some European centres PR occurs in the inpatient
setting. The following recommendations are presented
for two categories of patients: stable COPD and follow-
ing an exacerbation of COPD.
PICO 1a: Stable COPD
Summary of evidence: A Cochrane review that exam-
ined the evidence for PR in stable COPD8 included
65 RCTs. Outcomes of interest were confined to mea-
sures of exercise capacity and HRQoL. For exercise
capacity measured by the 6-min walk test (6MWT), PR
compared with usual care resulted in a mean differ-
ence (MD) of 44 m (95% CI: 33–55) in favour of PR
(38 studies, number of participants (n) = 1879 ). A sen-
sitivity analysis of studies with lower risk of bias yielded
a smaller MD in 6MWT for PR compared with usual
care (MD: 26 m, 95% CI: 21–32, 20 studies, n = 1188,
moderate quality evidence). This MD falls within the
range of the minimal important difference (MID)
(range: 25–33 m).24 For HRQoL, the effect of PR was
larger than the MID for all four domains of the Chronic
Respiratory Disease Questionnaire (CRQ) (i.e. Fatigue,
Emotional Function, Mastery and Dyspnoea) (MID is
0.5 units per domain)25 and the three components
(Symptoms, Impacts and Activity) and Total score of
the St George’s Respiratory Questionnaire (SGRQ)
(MID: −4 points)25 (SGRQ Total score MD: −6.89 units,
95% CI: −9.26 to −4.52, 19 studies, n = 1146, moderate
quality evidence). A sensitivity analysis of studies at
lower risk of bias yielded a slightly smaller MD for
SGRQ Total score, but this still exceeded the MID (MD:
−5.15 units, 95% CI: −7.95 to −2.36, seven studies,
n = 572, moderate quality evidence due to a high level
Respirology (2017) 22, 800–819 © 2017 The Authors
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of heterogeneity). Importantly, the Cochrane Airways
Group has decided to close the Cochrane review of PR,
stating that further RCTs comparing PR to conventional
care in COPD are no longer warranted as further RCTs
will not result in improved quality of evidence or
improved precision in the estimate of effect. The
Cochrane Airways Group believes that the remaining
issues around risk of bias, such as blinding of patients
and personnel, cannot be addressed with better study
design.26
Recommendation: The Guideline panel recom-
mends that patients with stable COPD should undergo
PR (strong recommendation, moderate quality
evidence).
Justification and implementation: This recommen-
dation places a high value on moderate quality evi-
dence of short-term (immediately following PR)
significant and clinically important effects on valued
outcomes of improved exercise capacity and
HRQoL.27,28
PICO 1b: Following an exacerbation of COPD
Summary of evidence: A Cochrane review that exam-
ined the evidence for PR following exacerbations of
COPD9 included 17 RCTs examining a range of out-
comes related to exercise capacity, HRQoL, subsequent
hospitalizations, mortality and adverse events. Of the
total 17 trials, five commenced PR within 2 weeks of
participants being discharged from hospital for an
exacerbation of COPD,29–33 similar to COPD manage-
ment in the Australian and New Zealand healthcare
context. Trials that commenced PR during an inpatient
stay were excluded. Meta-analyses of these five trials
are presented in Figure S1 (Supplementary Informa-
tion). A large effect on exercise capacity was found with
an MD in 6MWT of 56 m (95% CI: 27–85, two
studies,31,32 n = 116, moderate quality evidence), which
exceeded the MID.24 A large effect on HRQoL was also
found (SGRQ Total score MD: −10.64 units, 95% CI:
−15.51 to −5.77, five studies,28–32 n = 248, moderate
quality evidence), which exceeded the MID.25 PR com-
menced within 2 weeks of hospital discharge tended to
reduce repeat hospital admissions (OR: 0.30, 95% CI:
0.07–1.29, four studies,28–31 n = 187, moderate quality
evidence) with no effect on mortality (OR: 0.34, 95% CI:
0.05–2.34, two studies,28,31 n = 101, low quality evi-
dence). No adverse events were reported in these
studies.
Recommendation: The guideline panel recommends
that PR is provided after an exacerbation of COPD,
within 2 weeks of hospital discharge (weak recommen-
dation, moderate quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate quality evi-
dence of short-term (immediately following PR)
significant and clinically important effects on valued
outcomes of improved exercise capacity, HRQoL and
reduced hospital readmissions.27,28,34
PICO 2: Does PR affect HCU?
Background: Exacerbations are common in patients
with COPD and increase in prevalence with worsening
airflow limitation.35 Hospitalizations for severe exacer-
bations have major significance as they lead to disease
progression, deterioration in HRQoL and increased
mortality.36–38 Within Australia and New Zealand, con-
sistent with international data, severe exacerbations
leading to hospitalization are the primary driver of all
COPD-related medical care costs accounting for
50–75% of the direct COPD-associated healthcare
costs.6,39–41 During 2013–2014, the hospitalization rate
for COPD among patients aged 55 years and over was
1008 per 100 000 population in Australia39 and the
average cost of one hospital admission for COPD
(2011–2012 data) without complications or co-
morbidities (average length of stay (LOS): 5.0 days) was
$A5500, equivalent to more than 100 general practice
consultations.42 A majority of patients with COPD have
two or more co-morbidities,43 resulting in an estimated
doubling or tripling of the cost of care.44
Summary of evidence: The search strategy yielded
2546 citations of which 2505 citations were excluded
based on title and abstract. A total of 41 full papers
were extracted and reviewed. An additional four papers
were sourced from PR statements, systematic reviews
and clinical practice guidelines. In total, 45 papers
underwent full review of which nine RCTs reported the
effect of PR on HCU, defined as the reporting of
respiratory-related admissions, LOS (i.e. the mean or
median LOS for hospital admissions in the follow-up
period) or total bed days (i.e. the absolute numbers of
days in hospital in the follow-up period) and satisfied
the criteria for data extraction.29–32,45–49 In five trials,45–49
patients had stable COPD and in the remaining four
trials29–32 patients commenced PR no later than 3 weeks
following an exacerbation of COPD requiring hospitali-
zation. PR was delivered in hospital outpatient depart-
ments (six trials),29,31,32,45,46,48 within the patient’s home
(two trials)30,47 and in one trial, rehabilitation took place
within physiotherapy private practices.49 The follow-up
period for collection of HCU data ranged from
3 months, including the 8-week intervention period,29,31
to at least 12 months.32,45,46,48,49 Eight RCTs (n = 712)
evaluated the effect of PR on respiratory-related
admissions,29–32,45–47,49 four trials (n = 358) assessed
LOS32,45,47,48 and two trials (n = 241) reported the effect
of PR on total bed days.29,49 Two trials31,45 (n = 260)
demonstrated that PR significantly reduced hospital
admissions, both in those with stable COPD45 and
those who commenced PR within 7 days following dis-
charge from hospital for an exacerbation of COPD.31
A meta-analysis of the four trials29–32 (n = 194)
(Fig. S1, Supplementary Information) in which PR
commenced within 2 weeks of discharge after an exac-
erbation of COPD showed a trend towards a reduction
in readmissions following rehabilitation (OR: 0.30 (95%
CI: 0.07–1.29)). Of the four RCTs that assessed the
effect of PR on LOS, two reported a significant reduc-
tion in the mean LOS in the group receiving rehabilita-
tion (9.4 (SD: 10.2) days vs 18.1 (19.3) days, P = 0.02145
and 5.9 (0.33) days vs 9.3 (4.11) days, P = 0.035)47 with
no effect on LOS demonstrated in the remaining two
trials.32,48 The two trials29,49 that reported the effect of
PR on total bed days, one of which was in patients with
less severe COPD,49 found no difference between the
rehabilitation and control groups; however, neither trial
© 2017 The Authors
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was powered to detect changes in HCU. Quality of the
evidence was rated down for indirectness (high propor-
tion of males in some studies) and imprecision (small
number of participants and large CIs around the
estimates).
Only one of the nine RCTs was carried out in
Australia47 and none took place in New Zealand. An
additional RCT from Australia50 (published as abstract
only) showed a significant reduction in hospital admis-
sions and LOS following PR compared with a control
group. Owing to the lack of relevant RCTs carried out
in the local healthcare context, non-RCT evidence from
Australia or New Zealand was considered. Six non-
RCTs carried out in Australia that compared HCU in
the 12 months before and after PR were identified.51–56
All reported a reduction in hospitalizations for exacer-
bations of COPD following PR. One study was a large
sample (n = 267) trial that showed a significant reduc-
tion in admissions in the year after compared with the
year before a PR programme that comprised exercise
training alone or in combination with a structured
disease-specific education programme.51 A further five
observational studies (n = 975) of PR delivered in hos-
pital outpatient departments52–55 and in non-healthcare
facilities within the community56 also reported a reduc-
tion in hospitalizations in the 12 months following
rehabilitation. Because of their uncontrolled nature,
regression to the mean cannot be excluded in these
studies. Although there is a paucity of data from RCTs
carried out in Australia or New Zealand, given the large
body of evidence supporting the benefits of PR it is
unlikely that any further RCTs with long-term follow-
up, such as are needed for evaluating the effect of PR
on HCU, will be undertaken in Australia or
New Zealand due to the ethical concerns of denying
patients PR where this is available.
Recommendation: The guideline panel recommends
that patients with moderate-to-severe COPD (stable or
following discharge from hospital for an exacerbation
of COPD) should undergo PR to decrease hospitaliza-
tions for exacerbations (strong recommendation,
moderate-to-low quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate-to-low quality
evidence for outcomes that are important to patients.
The recommendation is ‘strong’ since, from a patient’s
perspective, avoidance of being hospitalized, house-
bound or confined to bed as a result of an exacerbation
has high importance.34
PICO 3: Is a home- or community-based PR
programme as effective as a hospital-based
PR programme?
Background: Despite strong evidence for the benefits
of PR highlighted in PICO 1, the proportion of patients
with COPD who participate in PR is low, estimated at
no more than 5–10% of patients with moderate-to-
severe COPD.10,11 Most PR programmes in Australia
and New Zealand have been offered in a hospital out-
patient setting and access is limited for patients who
do not live close to such centres. A common patient-
reported barrier to participating in hospital-based
programmes is difficulty with transport to the facility.57
PR programmes conducted in home- or community-
based settings could help to overcome these barriers
and potentially improve access and uptake.
To examine the evidence relating to the effectiveness
of home- and community-based PR programmes, three
separate comparisons were made:
• Is home-based PR more effective than usual care for
patients with COPD?
• Is home-based PR as effective as hospital-based PR
for patients with COPD?
• Is community-based PR more effective than usual
care for patients with COPD?
We defined home-based PR as programmes where
the intervention took place in the participant’s home,
and community-based rehabilitation as programmes
where the intervention took place in a community-
based setting (i.e. not a hospital and not at home). As
with all the other questions, the definition of PR inter-
vention in the Cochrane review8 was used as the crite-
rion for study inclusion with an additional criterion for
question 3 that the exercise therapy delivered must
include a lower limb endurance training component
(i.e. not just ‘general exercises’). This was to improve
applicability of the Guideline findings to Australian and
New Zealand practice, where prescription of lower limb
endurance exercise is a core part of the prescribed
exercise therapy in PR.58,59
PICO 3a: Is home-based PR more effective
than usual care for patients with COPD?
Summary of evidence: Eleven studies were identified
that made a direct comparison of home-based PR pro-
grammes with usual care control. Three examined
home-based programmes that commenced within
4 weeks of a hospital admission for an exacerbation of
COPD;30,60,61 in the other eight studies the participants
were in a stable clinical condition. In five studies,
home-based exercise sessions were directly supervised
to some degree, ranging from every session30 to once a
week47,62 or fortnightly.63,64 In all 11 studies, participants
were assessed in a hospital centre. Compared with
usual care, home-based PR in patients with stable
COPD resulted in large improvements in HRQoL sub-
stantially greater than the MID for all domains of the
CRQ and for the SGRQ Impacts and Activity compo-
nents, with similar improvements in those attending
PR following an exacerbation of COPD (reported for
CRQ domains of Dyspnoea, Fatigue and Mastery only),
based on moderate quality evidence. For example, in
stable COPD, the pooled MD between home-based PR
and control in CRQ-Dyspnoea was 0.77 units (95% CI:
0.44–1.10, two studies,62,65 n = 77) and CRQ-Fatigue
was 0.86 units (95% CI: 0.40–1.32 units, two studies,62,65
n = 77). For the 6MWT in stable COPD, the MD in
favour of home-based PR was 47 m (95% CI: 24–71,
three studies,62,63,66 n = 222, low quality evidence),
exceeding the MID (see Fig. S1 (Supplementary Infor-
mation) for meta-analyses). Quality of the evidence
was downgraded due to risk of bias from lack of asses-
sor blinding, imprecision and indirectness due to high
proportions of male participants (>90%).
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Recommendation: The guideline panel recommends
that home-based PR be offered to patients with COPD
as an alternative to usual care (weak recommendation,
moderate-to-low quality evidence).
Justification and implementation: This recommen-
dation places high value on moderate-to-low quality
evidence of short-term, moderate effects on outcomes
of importance to patients such as enhanced HRQoL,
reduced breathlessness and improved exercise toler-
ance. The strength of the recommendation was ‘weak’
due to the differing models of home-based rehabilita-
tion programmes with lack of evidence regarding the
optimal format. As many of the exercise sessions in
home-based programmes were unsupervised, it is
likely that regular contact with a physiotherapist or
accredited exercise physiologist who is experienced in
prescribing exercise-based rehabilitation is critical to
ensure that patients receive a sufficient exercise dose
to obtain programme benefits. Most of the evidence is
derived from participants with stable COPD (more than
4 weeks after an exacerbation of COPD) providing
greater confidence in recommending implementation
of home-based PR in this group.
PICO 3b: Is home-based PR an effective
alternative to hospital-based PR for patients
with COPD?
Summary of evidence: A search of the literature
located 278 citations including three systematic
reviews8,67,68 of studies examining the effectiveness of
home-based PR. One additional RCT from Australia,
comparing home-based rehabilitation to a standard
hospital-based programme,69 was published after the
search was conducted and was included because of its
direct relevance to this question. Of the included stud-
ies, six made a direct comparison of home-based with
hospital-based PR.69–74 Two studies were powered for
equivalence.69,71 In one study, every session of home-
based exercise was directly supervised by a physiother-
apist;74 the other five home-based programmes69–73
included supervision of the initial session only and/or
telephone contact. Three of the studies, including the
two largest trials,69,71 reported regular weekly contact
with participants in the home-based intervention69,71,73
but frequency of contact was unreported in the other
three studies.70,72,74
Improvements gained post-PR in HRQoL were not
statistically different or clinically important between
programmes conducted in home and hospital settings
(e.g. CRQ-Dyspnoea MD: 0.00 units, 95% CI: −0.22 to
0.23, three studies,69–71 n = 414 (Fig. S1, Supplementary
Information)). However, within-group changes
exceeded the MID in both settings.69–71 This finding of
similar benefits in HRQoL was consistent in all studies
for measures using the CRQ and SGRQ. Changes in
HRQoL in both settings exceeded the MID for some
but not all domains. Changes in exercise tolerance
were not clinically or statistically different between
home- and hospital-based programmes for the 6MWT
(MD: 3.5 m, 95% CI: −12.9 to 19.6, n = 255 (Fig. S1,
Supplementary Information))69,70,72 with similar find-
ings for endurance treadmill test73 and maximal
incremental exercise tests.73,74 Quality of the evidence
was rated down for risk of bias due to lack of blinding
and indirectness due to gender imbalance (60–100% of
participants in each study were males).
Recommendation: The guideline panel recommends
that home-based PR, including regular contact to facili-
tate exercise participation and progression, be offered
to patients with COPD as an alternative to hospital-
based PR (weak recommendation, moderate-to-low
quality evidence).
Justification and implementation: This recommen-
dation places high value on moderate quality evidence
of no significant differences in short-term outcomes of
importance to patients (such as enhanced HRQoL,
reduced breathlessness and improved exercise
tolerance), whether the PR is a hospital-based or
home-based programme. The strength of the recom-
mendation was ‘weak’ due to the differing models of
home-based rehabilitation programmes with lack of
evidence regarding the optimal format. As many of the
exercise sessions in home-based programmes were
unsupervised, it is likely that regular contact with a
physiotherapist or accredited exercise physiologist who
is experienced in prescribing exercise-based rehabilita-
tion is critical to ensure that patients receive a suffi-
cient exercise dose to obtain programme benefits.
PICO 3c: Is community-based PR more
effective than usual care for patients
with COPD?
Six studies that met our definition of community-based
PR49,75–79 were identified from an existing Cochrane
review.8 An additional search covering the period not
included in the Cochrane review (March 2014 to
February 2016) identified one further study.80
Summary of evidence: Of the seven included stud-
ies, four implemented community-based programmes
with exercise sessions of at least moderate intensity
supervised twice a week49,75,78,80 (n = 259), consistent
with the provision of PR in Australia and New Zealand.
In other studies, the exercise component was of low
intensity79 or implemented once weekly.76,77 Compared
with usual care, community-based PR resulted in mod-
erate improvements in overall HRQoL (SGRQ Total
score MD: −4.2 units, 95% CI: −6.5 to −1.9, three
studies,49,78,80 n = 229). Exercise frequency and intensity
in these three studies were consistent with typical
hospital-based programmes in the Australian and
New Zealand settings. Pooled data from studies that
used the CRQ to measure HRQoL76,79 indicated a
change in favour of the intervention for the CRQ Dys-
pnoea domain only (MD: 0.53 units, 95% CI: 0.03–0.80,
two studies,76,79 n = 343) with no differences in other
domains (Fig. S1, Supplementary Information). Both of
these studies76,79 implemented low intensity or fre-
quency of exercise which may help to explain their lack
of effect on the other domains of the CRQ. Endurance
exercise capacity showed clinically meaningful
improvements from community-based PR compared
with control (cycle endurance test MD: 221 s, 95% CI:
5–437)49 and treadmill (MD: 194 s).80 Evidence is lim-
ited for effectiveness on 6MWT and incremental shuttle
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walk test (ISWT) due to risk of bias (high attrition and
lack of blinding),75–79 imprecision (6MWT protocol vari-
ation)49 and indirectness (low intensity and frequency
of exercise).76,77,79
Recommendation: The guideline panel recommends
that community-based PR, of equivalent frequency and
intensity as hospital-based programmes, be offered to
patients with COPD as an alternative to usual care
(weak recommendation, moderate quality evidence).
Justification and implementation: This recommen-
dation places high value on moderate quality evidence
of short-term, moderate effects on outcomes of impor-
tance to patients such as enhanced HRQoL, reduced
breathlessness and improved exercise tolerance. None
of the studies reported whether participants within
4 weeks after an exacerbation of COPD were included,
therefore the recommendation cannot be extended to
this group. The optimal model for community-based
programmes is not known; however, the exercise train-
ing component must be delivered at a similar fre-
quency and intensity as hospital-based programmes in
order to achieve clinically meaningful benefits for
patients.
Implementation of PR in home- or community-based
settings could help overcome common barriers of
availability, access and difficulty of travelling to
hospital-based programmes expressed by patients with
COPD.57
PICO 4: In patients with mild disease
severity, is PR more effective than
usual care?
Background: Patients with COPD present with a range
of disease severities, from mild to severe. The
Australian COPD-X Guidelines7 and an international
PR statement15 recommend referral to PR for all
patients, regardless of the degree of disease severity.
Spruit et al. suggest that patients with mild disease may
benefit from preventative strategies and maintenance
of physical activity, and PR may be, but is not necessar-
ily included in these strategies.15 Whilst PR is supported
by Level I evidence (PICO 1), the effectiveness in mild
disease is not well established. The COPD-X Guidelines
define mild COPD as a forced expiratory volume in 1 s
(FEV1) between 60% and 80% predicted, with few
symptoms, breathlessness on moderate exertion and
little or no effect on daily activities.7
Summary of evidence: The search strategy yielded
34 citations and hand searching identified a further
4 citations, 38 in total. Based on evaluation of the
abstracts and titles, 30 citations were excluded and a
further 4 citations were excluded on review of the full
papers, leaving 4 papers for full review and data extrac-
tion. Studies defined mild disease in two ways: based
on an FEV1 cut-off
81–83 or symptoms.84 The studies
based on FEV1 either did not report detailed data for
the mild group specifically and did not respond to
requests for data,82 or were of very low quality.81,83 As
such, the focus of this question was limited to studies
that used symptoms to categorize disease severity.
A systematic review84 that examined the effectiveness
of PR in COPD patients with a modified Medical
Research Council (mMRC) breathlessness score ≤1
included four RCTs49,78,79,82 (n = 489). Compared with
usual care, PR in patients with mild COPD resulted in
short-term (up to 6 months) improvements in HRQoL;
MD in the SGRQ was −4.2 units (95% CI: −4.5 to −3.9),
exceeding the MID85 (two studies,78,82 n = 207, moder-
ate quality). Effects on HRQoL were no longer evident
at the longest follow-up period of 24 months. Func-
tional exercise capacity (6MWT) showed a mean
improvement of 25.7 m (95% CI: 15.8–35.5 m, four
studies,49,78,79,82 n = 313, moderate quality evidence).
This just reached the lower end of the MID.24 Quality
of the evidence was rated down for risk of bias, particu-
larly lack of assessor and participant blinding.
Recommendation: The guideline panel recommends
that patients with mild COPD (based on symptoms)
undergo PR (weak recommendation, moderate-to-low
quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate quality evi-
dence of clinically significant short-term improvement
in functional exercise capacity and HRQoL, and low
value on cost and uncertainty regarding patient prefer-
ence. Whilst benefits from PR in patients with sympto-
matically mild disease are evident, we recognize that
patients are heterogeneous in terms of lung function
and symptoms. As such, further research is needed to
examine the effect of PR in mild disease based on a
multidimensional assessment of these variables and an
objective assessment of disease severity.
PICO 5: Are programmes of longer duration
more effective than the standard 8-week
programmes?
Background: The duration of PR programmes reported
in the literature varies from 4 weeks to 18 months. PR
programmes of 8-week duration are commonly recom-
mended in PR statements15 and guidelines.12–14 While a
large number of PR programmes in Australia and
New Zealand are conducted over an 8-week
duration,58,59 it is unclear whether significant benefits
may be conferred from programmes of a longer
duration.
Summary of evidence: The search strategy to deter-
mine whether differences exist between 8-week PR pro-
grammes and those of longer duration, in terms of
exercise capacity and HRQoL, yielded 6712 citations, of
which 6698 citations were excluded based on title and
abstract. Fourteen papers were reviewed in full text;
however, no RCTs were identified that directly com-
pared PR programmes of 8 weeks to programmes of
longer duration.
Recommendation: The panel is unable to make a
recommendation due to lack of evidence evaluating
whether programmes of longer duration are more
effective than the standard 8-week programmes.
Justification and implementation: There is no
direct evidence comparing 8-week programmes to
those of longer duration. In order to provide some
guidance for programme duration, we extracted data
from trials included in the most recent Cochrane
review of PR8 that were consistent with current
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Australian and New Zealand practice of two to three
supervised exercise sessions per week. We compared
outcomes from RCTs of 8-week PR programmes and
RCTs of 12-week PR programmes. For the outcome of
6MWT, there were six RCTs of 8-week programmes
compared with usual care (n = 218)86–91 and four RCTs
of 12-week programmes compared with usual care
(n = 225).72,75,92,93 Meta-analyses demonstrated an MD
for 6MWT of 77 m (95% CI: 54–100) for the 8-week pro-
grammes and 57 m (95% CI: 27–88) for the 12-week
programmes. No significant difference in improvement
in 6MWT between programmes of different durations
was observed (P = 0.31). For the outcome of SGRQ,
there were five RCTs of 8-week programmes compared
with usual care (n = 182)86–88,91,94 and only one RCT of
a 12-week PR programme compared with usual care
(n = 26);92 thus, there were insufficient data to compare
SGRQ between programmes of 8- and 12-week dura-
tion for HRQoL. For the 8-week programmes versus
usual care, the MD for SGRQ Total score was −9.6 units
(95% CI: −15 to −4) which is greater than the MID of −4
points.25 The MD for SGRQ Total score for the study of
a 12-week PR programme was −5 units (95% CI: −14 to
4) (meta-analyses are presented in Fig. S1
(Supplementary Information)).
PICO 6: Does ongoing supervised exercise at
a lower frequency than the initial PR
programme maintain exercise capacity and
quality of life to 12 months in patients
with COPD?
Background: These Guidelines recommend the use of
PR programmes for patients with stable COPD and fol-
lowing an exacerbation of COPD (PICO 1a and b).
However, functional exercise capacity and HRQoL
often decline in the 12 months following PR comple-
tion.95,96 Consequently, ongoing supervised exercise
programmes are offered following PR. In Australia, 72%
of PR programmes offer supervised maintenance exer-
cise programmes (Lung Foundation Australia, unpub-
lished data) at a lower frequency than the initial
programme (e.g. once a week or once a month).
Whether this is the best way to maintain the benefits
gained from PR to 12 months and beyond remains
unclear.
Summary of evidence: The search strategy yielded
51 citations of which 32 full papers and 8 abstracts
were extracted and reviewed. Of these, the recommen-
dations in this Guideline are based on the review of
11 RCTs that reported maintenance exercise pro-
grammes consisting of supervised exercise at a lower
frequency than the initial PR programmes.49,79,95–103 A
comparison across the studies was challenging given
that three studies reported long-term changes com-
pared with the beginning of the PR programmes (pre-
rehabilitation) and eight studies compared outcomes to
the end of the PR programmes (post-rehabilitation).
Furthermore, studies were heterogeneous in the deliv-
ery of interventions (e.g. frequency of supervised exer-
cise) and measurement of outcomes.
When weekly supervised exercise was performed as
a maintenance exercise programme, one study (n = 22)
reported that at 12 months, functional exercise capacity
and HRQoL were not significantly different to pre-
rehabilitation and showed no differences compared
with a group who was supervised monthly.100 In con-
trast, in three studies (n = 204) where results at
12 months were compared with post-rehabilitation,
weekly supervised exercise maintained functional exer-
cise capacity,79,103 peak exercise capacity,103 endurance
exercise capacity103 and HRQoL.99,103 However, there
was no difference compared with the control groups
that consisted of standard care or unsupervised home
exercise with regular review.79,99,103 In studies where
supervised exercise sessions were progressively
reduced (weekly supervised exercise followed by sec-
ond weekly, followed by monthly) during the mainte-
nance period, two studies (n = 77) reported that at
12 months, exercise capacity was better than pre-
rehabilitation in the intervention groups, and that the
control groups (unsupervised home exercise) had
declined below pre-rehabilitation levels.98,102 However,
no between-group differences were reported.98,102
Based on the results of the studies described above,
there appears to be no added benefit gained from
weekly supervised exercise or a reducing frequency of
supervised exercise compared with unsupervised home
exercise with regular review, as a maintenance exercise
programme.
When monthly or three monthly supervised exercise
was performed as a maintenance exercise programme
in five studies (n = 512), there was a significant decline
at 12 months in exercise capacity and HRQoL in both
the intervention and control groups, compared with
both pre-49,101 and post-rehabilitations.95–97 Based on
the results of these studies, maintenance exercise pro-
grammes of monthly or three monthly supervised exer-
cises are insufficient to maintain exercise capacity or
quality of life to 12 months.
The overall quality of the evidence from the studies
described above was low and rated down for risk of
bias (lack of random sequence generation and assessor
blinding with unclear allocation) and imprecision
(small numbers of studies and participants contributing
to meta-analysis with some studies having miss-
ing data).
Recommendation: The guideline panel recommends
that: (i) more research is needed to determine the opti-
mal model of maintenance exercise programmes
(‘in-research’ recommendation); (ii) supervised main-
tenance programmes of monthly or less frequently are
insufficient to maintain the gains of PR and should not
be offered (weak recommendation, low quality
evidence).
Justification and implementation: The recommen-
dation places a high value on low quality evidence that
monthly supervised ongoing exercise is insufficient to
maintain outcomes of importance to patients com-
pared with standard care. While there may be benefits
of weekly, supervised maintenance exercise, current
low quality evidence suggests that it is no better than
standard care of unsupervised exercise with regular
review. When participants were surveyed following the
completion of a 12-month maintenance exercise pro-
gramme, positive attitudes towards both the supervised
and unsupervised maintenance exercise programmes
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were reported, with no between-group differences
found for the importance of exercise, the benefits of
the programme or the importance of support from the
physiotherapist.104 Further research is required to clar-
ify the benefits, location and the cost benefit of weekly
supervised exercise as a maintenance programme.
However, some form of regular ongoing exercise
should be encouraged once PR has been completed to
sustain the benefits gained.
PICO 7: Does a structured education
programme enhance the benefits of PR?
Background: In Australia and New Zealand, the major-
ity of PR programmes have reported providing a struc-
tured education programme.58 Health education in this
format is provided by members of a multidisciplinary
team to patients as a group audience. Topics are pre-
determined and cover the disease (COPD) and aspects
of its management, and may be accompanied by writ-
ten material. Structured education in PR is reported to
be valued by patients with COPD.105
Summary of evidence: The search strategy yielded
278 citations of which 250 were excluded based on title
and abstract. A further 24 citations were excluded on
review of the full paper, leaving 4 papers for full review
and data extraction.
Two RCTs compared a twice weekly outpatient PR
programme that included supervised exercise training
and a structured education programme to supervised
exercise training alone.51,106 One of these RCTs was a
large Australian trial (n = 267).51 Patients in both mod-
els demonstrated significant improvements in key out-
comes; however, there were no additional benefits
attributable to the education programme in exercise
capacity (6MWT), HRQoL (CRQ), dyspnoea (Medical
Research Council (MRC) dyspnoea score), self-efficacy
or health behaviour in the short term or long term
(12 months). In the Australian trial, the findings were
limited by a low completion rate in the intervention
group (60%) and a large loss to follow-up (26%) that
was greater in the exercise-only group.51 However, in
the secondary outcome of HCU, for which data were
available for all participants, there remained no
enhanced benefit of the education programme in terms
of hospitalizations in the 12 months following PR. The
smaller trial (n = 22) found that the lecture series nega-
tively affected emotional function compared with exer-
cise training alone (P = 0.03), despite the additional
attention participants received from healthcare profes-
sionals.106 This trial was not adequately powered to
detect differences between groups in most outcomes
and lacked blinding. Similarly, an observational study
of Italian patients who elected to attend a structured
education programme (n = 226) or not (n = 59) in con-
junction with supervised exercise training demon-
strated no differences between groups in exercise
capacity (6MWT), breathlessness (MRC), HRQoL
(SGRQ) or responses to a knowledge and learning
impact questionnaire.107 An evaluation of a new struc-
tured education programme for COPD in PR delivered
in 11 hospitals and community-based programmes in
Northern Ireland demonstrated high patient satisfac-
tion and a significant improvement in knowledge,
understanding and self-efficacy.108 The results from
these observational studies are at high risk of bias due
to study design, selection bias and lack of
blinding.107,108
Recommendation: The guideline panel recommends
that PR be offered to all patients with COPD, irrespec-
tive of the availability of a structured multidisciplinary
group education programme (weak recommendation,
moderate-to-low quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate-to-low quality
evidence from a small number of studies. The role of
education within PR is highly valued by patients and
clinicians. The provision of knowledge in an appropri-
ate format is an essential component of effective
patient self-management. It is possible that behaviour
change in PR may be further promoted with the addi-
tion of self-management interventions.15,109 The Guide-
line panel only reviewed structured group education
and did not review individualized models of education
or self-management interventions for patients with
COPD and therefore cannot make a recommendation
regarding these strategies within the context of PR.
PICO 8: Do patients who experience oxygen
desaturation during exercise have greater
improvements if oxygen supplementation is
provided during training?
Background: Exercise-induced oxygen desaturation
(EID) is common among patients with COPD, with an
Australian study indicating that 47% of those referred
to a PR programme demonstrated a decrease in oxygen
saturation to <90% during a 6MWT.110 It is plausible
that the intensity of exercise training achieved in a PR
programme by patients with COPD who experience
EID may be compromised, particularly if clinicians
attempt to minimize EID by decreasing training inten-
sity or imposing mandatory rests. A reduction in train-
ing intensity may have repercussions for the magnitude
of training effect achieved. Consequently, oxygen sup-
plementation may be provided in PR programmes for
patients with COPD who experience EID. It has been
known for over 50 years that oxygen supplementation
can improve exercise capacity in COPD111 but the effect
of oxygen supplementation during exercise training for
patients with COPD who experience EID is unclear.
Summary of evidence: The search strategy yielded
2052 citations of which 2042 were excluded based on
title and abstract. A total of 10 full papers were
extracted and reviewed. Of these, four RCTs were
identified112–115 addressing the question. The level of
evidence of these RCTs was low due to imprecision
and high risk of bias from lack of assessor blinding and
drop-out.
The results from the RCTs examining whether oxy-
gen supplementation should be provided during exer-
cise training for patients with COPD who experience
EID were inconsistent. Most of the RCTs112–114 indicated
that there was no difference using supplemental oxy-
gen versus no supplemental oxygen (i.e. compressed
air or room air) on exercise capacity, breathlessness
and levels of anxiety/depression following exercise
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training in patients with EID. In contrast, one study
demonstrated greater improvement in endurance walk-
ing capacity using supplemental oxygen during training
compared with no supplemental oxygen (i.e. room
air).115 However, the exercise testing protocol in this
study at baseline and follow-up was not consistent as
the end tests were performed on the gas to which each
participant was randomized, and compared with base-
line assessment which was performed on room air.
This protocol eliminated the ability to conclude
whether improvements were due to the acute effects of
the supplemental oxygen or due to a training effect. No
RCTs examined mortality or HCU.
Recommendation: The guideline panel recommends
that further research of oxygen supplementation during
training is required in patients with COPD who have
exercise-induced desaturation to reduce the uncer-
tainty around its lack of effect to date (‘in-research’
recommendation).
Justification and implementation: There is insuffi-
cient evidence to confirm the benefits of oxygen sup-
plementation during exercise training compared with
no oxygen supplementation in patients with COPD
who have EID. Currently, supplemental oxygen is used
in most Australian PR programmes to ensure safety
and relieve symptoms for patients with COPD experi-
encing EID. The provision of supplemental oxygen dur-
ing PR increases programme costs and restricts the
venues where training can be delivered. More research
is needed to provide clarity as to whether supplemental
oxygen during exercise training should be used in
patients with COPD who experience EID.
PICO 9: Is PR effective in chronic respiratory
diseases other than COPD?
PICO 9a: Is PR effective in patients with
bronchiectasis?
Background: Bronchiectasis is characterized by bron-
chial dilatation secondary to inflammation, infection
and reduced mucociliary clearance. Patients with bron-
chiectasis experience persistent cough with sputum
production, reduced exercise tolerance, breathlessness,
fatigue and poor HRQoL. Exacerbations of bronchiecta-
sis are common and are an indicator of poor progno-
sis.116 Treatment for bronchiectasis aims to improve
control of symptoms, reduce exacerbation frequency,
maintain lung function and optimize HRQoL. Such
treatment includes careful antibiotic selection and may
include airway clearance techniques.117
Summary of evidence: To inform this Guideline, a
systematic review was used.18 The search strategy for
this review yielded 82 citations and of these, 3 RCTs
with a total of 135 participants with stable bronchiecta-
sis were included.118–120 HRQoL improved in the PR
group compared with control (SGRQ Total score MD:
−4.6 points, 95% CI: −6.5 to −2.6, two studies, n = 103,
moderate quality evidence). The ISWT improved by
64.5 m compared with control (exceeding the MID;24
95% CI: 49.4–79.6 m, three studies,118–120 n = 122, mod-
erate quality evidence). Quality was rated down for risk
of bias (lack of assessor blinding in some studies). A
single study (n = 76) reported no difference between
groups for anxiety or depression, although the number
of participants with mood disturbance at baseline was
low.118 No studies reported HCU, although one trial
reported a lower frequency of exacerbations in the PR
group, with a longer time to first exacerbation
(8 months vs 6 months, P = 0.047).118 Longer term
follow-up in one study showed that benefits of PR were
not sustained at 6 or 12 months.118
Recommendation: The guideline panel recommends
that patients with bronchiectasis undergo PR (weak
recommendation, moderate quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate-to-low quality
evidence of clinically significant improvements in exer-
cise capacity and overall HRQoL, and a low value on
uncertainty regarding magnitude and duration of bene-
fit. All trials of PR for bronchiectasis have included air-
way clearance techniques, which may not be a
standard component of PR in some settings. As a
result, some providers may require extra training in
order to deliver PR for patients with bronchiectasis.
PICO 9b: Is PR effective in patients with ILD?
Background: The ILDs are a diverse group of over
200 chronic lung conditions including idiopathic pul-
monary fibrosis (IPF), connective tissue-related ILD,
dust-related ILD, granulomatous ILD (e.g. sarcoidosis)
and rarer ILDs such as lymphangioleiomyomatosis.
They are characterized by varying degrees of interstitial
inflammation and fibrosis, a restrictive ventilatory pat-
tern and marked exercise-induced hypoxaemia.
Patients with ILD experience distressing breathlessness
on exertion, significant fatigue, reduced HRQoL, as well
as high levels of anxiety and depression. There are lim-
ited treatment options for many ILDs. For instance in
IPF, the most common and most lethal ILD, new phar-
macotherapies can slow disease progression but do not
provide cure.23 In this setting, interventions that
improve functional capacity and well-being may have
an important role.
Summary of evidence: A Cochrane review that
examined the evidence for PR in ILD19 included nine
RCTs, of which five were published as abstracts. Com-
pared with usual care, PR resulted in moderate
improvements in overall HRQoL (standardized MD
(SMD): 0.59, 95% CI: 0.2–0.98, three studies, n = 106,
low quality evidence). Similar improvements were seen
for breathlessness and fatigue domains of HRQoL
instruments. Compared with usual care, the 6MWT
improved by 44 m (95% CI: 26–63, five studies,
n = 162, moderate quality evidence), exceeding the
MID.24 Effects on HRQoL, symptoms and exercise
capacity were no longer evident at 6 months following
programme completion.19 Quality of the evidence was
rated down for risk of bias, particularly lack of assessor
blinding, and for imprecision. Improvements of similar
magnitude were reported in a Cochrane review of exer-
cise training in dust-related respiratory disease, which
included a small number of participants with dust-
related ILD.121 No RCTs have examined the impact of
PR on anxiety or depression in this setting. Single stud-
ies have reported effects of PR on 6-month mortality122
and HCU,123 with no differences between groups.
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Recommendation: The guideline panel recommends
that patients with ILD undergo PR (weak recommenda-
tion, low quality evidence).
Justification and implementation: This recommen-
dation places a high value on moderate-to-low quality
evidence of short-term, moderate size effects on out-
comes of importance to patients such as reduced
breathlessness and enhanced HRQoL. However, the
choice to undertake PR may be influenced by the rela-
tively short duration of benefit. There is currently no
evidence to suggest that the recommendation should
vary according to the type of ILD, or that the exercise
prescription should vary from that provided to patients
with COPD. Because many patients with ILD use sup-
plemental oxygen and/or experience profound
exercise-induced desaturation, consideration should be
given to providing PR in a setting where supplemental
oxygen can be provided during training.
PICO 9c: Is PR effective in patients with PH?
Background: PH is defined as an increase in the resting
mean pulmonary arterial pressure to at least 25 mm Hg
on right heart catheterization.124 Many patients with PH
experience breathlessness on exertion; however, a
range of other important symptoms may be present,
including fatigue, dizziness, chest discomfort, chest
pain, palpitations, cough, pre-syncope, syncope, lower
limb oedema and abdominal distension. For patients
from Group 1 PH (pulmonary arterial hypertension,
PAH), specific pharmacotherapies are available and
have markedly improved prognosis. However, many
patients who are stable on medical therapy report sig-
nificant exercise limitation and impaired HRQoL.125,126
Summary of evidence: A Cochrane review compar-
ing exercise training to control in PH20 included six
RCTs (n = 206) with varying classifications of PH. All
participants were stable on medical therapy. Three of
the RCTs were from the same group in Germany
(n = 137) and used a 3-week inpatient rehabilitation
programme,125,127,128 a model that is not available in
Australia or New Zealand. HRQoL outcomes showed
that, compared with usual care, exercise training
improved the physical function score of the 36-Item
Short Form Health Survey version 2 (SF-36v2) (MD: 6.3
points, 95% CI: 0.8–13.3, four studies,125,126,129,130
n = 118, low quality evidence) and the mental health
score of the SF-36v2 (MD: 7.4 points, 95% CI: 2.6–12.2,
three studies,128–130 n = 87, very low quality evidence).
Compared with usual care, the 6MWT improved
by 60 m (95% CI: 30–90, five studies,125,127–130 n = 165,
low quality evidence), which exceeded the MID by a
large amount.24 The studies which relied totally on
outpatient-based exercise programmes,129,130 consistent
with the PR model in Australia and New Zealand,
reported a smaller MD in 6MWT favouring the exercise
group of 34 m (95% CI: 1–67) (n = 36), which still
exceeded the MID.24 No RCTs evaluated anxiety,
depression or HCU. Quality of the evidence was rated
down for risk of bias (lack of random sequence genera-
tion or assessor blinding), indirectness (may represent
a selected subgroup of patients with PH) and impreci-
sion (small numbers of studies and participants contri-
buting to meta-analysis).
None of the studies reported significant adverse
events during exercise training such as progression of
symptoms, progression of PH, right heart failure or
death. One study reported that 3 of the 15 exercise
group participants had symptoms during training
which comprised dizziness without fainting immedi-
ately following cycle ergometer training (n = 2) and
desaturation from 88% to 74% despite oxygen therapy
(n = 1).125 In a cohort study, the same investigators
reported that 25 of the 183 patients (14%) experienced
adverse events during a 3-week inpatient rehabilitation
programme including syncope, pre-syncope, acute res-
piratory infection, supra-ventricular tachycardia and
haemoptysis.131
Recommendation: The guideline panel recommends
that patients with PH undergo PR (weak recommenda-
tion, low quality evidence).
Justification and implementation: This recommen-
dation places a high value on low quality evidence of
moderate effects on outcomes of importance to
patients (quality of life and exercise capacity). Most evi-
dence relates to inpatient exercise training (68% of par-
ticipants who have undergone exercise training in
RCTs), which may allow closer monitoring and supervi-
sion than in outpatient programmes and is not availa-
ble in Australia or New Zealand. However, no
important adverse events have been reported in trials
of outpatient exercise training, so there is currently no
evidence to suggest that the recommendation should
vary according to programme setting. Patients should
be stable on pharmacotherapy prior to undertaking an
exercise training programme. There is no evidence to
suggest that the recommendation should vary accord-
ing to class of PH. International guidelines for PH man-
agement currently recommend that exercise training
should be undertaken ‘…by centres experienced in both
PH patient care and rehabilitation of compromised
patients’.124
DISCUSSION
These PR Guidelines address questions considered by
a representative multidisciplinary panel of experts in
the field and the COPD consumer group to be impor-
tant in the context of Australian and New Zealand
health services. The PICO questions were limited to
<10 and we recognize that these do not encompass all
the important questions pertaining to PR. Each ques-
tion was addressed and recommendations formulated
using an evidence-based, systematic process.21 Strong
recommendations were able to be made regarding the
effectiveness of PR in improving exercise capacity,
HRQoL and reducing hospital admissions for patients
with COPD. While there are resources required to pro-
vide PR, the cost per quality-adjusted life year (QALY)
ratios are within the bounds considered to be cost-
effective and likely to result in financial benefits to
health services.132 Given the compelling evidence of the
benefits of PR, policymakers should ensure appropriate
strategies are in place to enable equitable access to PR
for patients with COPD. Increased availability of PR
programmes and referral to these programmes are vital
to ensure improved patient access and increased
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patient participation in this effective evidence-based
intervention.
There were gaps in the available evidence to answer
some of the questions. In particular, there was no
direct evidence to determine whether PR programmes
of longer than 8-week duration were more effective
than the standard 8-week programmes that are com-
mon in Australia and New Zealand.58,59 Some evidence
from meta-analyses of programmes of 8-week duration
(in which exercise was supervised two to three times
per week) provides confidence that this programme
duration improves exercise capacity and HRQoL. Lim-
ited evidence was available to guide practice for the
use of supplemental oxygen during exercise training in
patients with COPD who experience EID but who are
not prescribed long-term oxygen therapy. As approxi-
mately 47% of patients referred to PR in Australia
experience EID,133 further high quality research is
needed in this area to determine if there are benefits
of providing supplemental oxygen during training and
whether these benefits are greater than those that can
be achieved with training on room air in this patient
group. Such research will help to determine whether
patients who experience EID need to attend a PR pro-
gramme where supplemental oxygen is available. Cur-
rently, a large Australian RCT is underway examining
oxygen supplementation during exercise training in
patients COPD who have EID.134 Optimal interventions
for the long-term maintenance of improvements after
completion of a PR programme could not be deter-
mined, other than the evidence suggesting that
monthly maintenance programmes are not worth-
while. Maintenance of the benefits of PR is an impor-
tant area of future research and may link with
behaviour change and self-management
interventions,109 although these were not addressed in
the Guidelines.
While most evidence for PR comes from hospital-
based programmes, the Guideline review has demon-
strated growing evidence for the effectiveness of PR in
other venues such as community or home settings.
Such settings may improve access to programmes by
eliminating some of the known barriers to programme
attendance,57 as well as providing patients with choices
around venues such as community-based programmes,
home-based programmes or programmes provided in
primary care by private practitioners. Availability of PR
programmes in a variety of settings may improve pro-
gramme access and adherence. Appropriate funding is
a driver for provision of PR. Currently in Australia, PR
is funded through hospital funding models based on
the Independent Hospital Pricing Authority, Tier
2 (non-admitted hospital services) classifications135 and
related pricing.136 While such funding enables some
rehabilitation programmes to be provided via the hos-
pital system, major changes in funding models are
required to enable the wider provision of PR in
primary care.
In terms of patient education, the Guideline only
reviewed patient education delivered in a structured
group format, as this is how education has traditionally
been delivered in Australian and New Zealand PR pro-
grammes.58,59 The limited number of RCTs showed no
additional benefit of structured education to a PR
programme compared with PR alone. A structured
educational format may not be suitable for all patients
whose learning styles, needs and cognitive abilities
may vary. It was beyond the scope of the Guidelines to
further explore this area, in particular self-management
education was not addressed. Our findings do not
diminish the importance of education for patients
undertaking PR; rather this reinforces the need to
establish the most effective methods to assist indivi-
duals with COPD to gain the skills and knowledge they
require to optimally manage their disease.
The review of PR for patients with mild COPD (based
on symptoms) found clinically meaningful benefits in
HRQoL and exercise capacity. Traditionally, PR pro-
grammes in Australia and New Zealand have mainly
included patients with moderate-to-severe disease,
consistent with the initial studies underpinning the effi-
cacy of PR.8 Many patients with mild COPD in
Australia and New Zealand are managed by their gen-
eral practitioner in primary care and are not often
referred to PR. However, our review findings demon-
strate beneficial outcomes from PR across the spectrum
of disease. While the most cost-effective model for pro-
viding PR for patients with mild disease is unknown, it
is possible that less costly community health and fit-
ness programmes linked with high quality COPD-
specific education programmes, which are becoming
more available online,137 are worth evaluating.
There is growing evidence of the effectiveness of PR
for chronic lung diseases other than COPD. The Guide-
lines have provided reviews of the benefits of PR for
patients with bronchiectasis, ILD and PH. The recom-
mendations in favour of PR for patients with these diag-
noses suggest that inclusion criteria should facilitate the
participation of such patients in PR programmes in
Australia and New Zealand. Practitioners providing PR
for patients with bronchiectasis, ILD and PH should
have adequate skills and knowledge to treat these
patient groups and, for some patients, PR may need to
be provided in centres with disease-specific expertise.
Given the higher incidence of COPD in Indigenous
Australian4 and New Zealand communities,5 it is
important that Indigenous patients with COPD have
access to PR. One barrier to attendance at PR may be
the lack of attention to cultural needs within main-
stream programmes.138 Currently in Australia, no PR
programmes are specifically designed to accommodate
the cultural needs of Aboriginal and Torres Strait
Islander Peoples and there is little empirical data on
what these needs are. In New Zealand, PR programmes
provided for Maori individuals by Maori organizations
have identified that attendance is enhanced by the
opportunity to make culturally meaningful connections
with other patients and staff within the programme,
having culturally appropriate information available and
communicating in a common Maori language.138 It is
imperative that greater efforts are made to ensure safe
cultural environments for the delivery of PR, either by
Indigenous health professionals providing the PR pro-
grammes or by mainstream programmes providing a
culturally appropriate environment to encourage and
maintain attendance.
These PR Guidelines have evaluated the evidence
related to the questions posed and provide general
© 2017 The Authors
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recommendations. For information on the practical
aspects of providing PR and individualizing interven-
tions for patients, clinicians should access the Pulmo-
nary Rehabilitation Toolkit139 which provides extensive
information on establishing a PR programme, patient
assessment, exercise training, patient education and
patient reassessment.
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